Scientists at the University of California, San Francisco have discovered a common genetic driver of aggressive meningioma, which can help clinicians detect this dangerous cancer earlier and find new treatments for these difficult-to-treat tumors. A research team led by Dr. David Raleigh found that increased gene activity called FOXM1 seems to be responsible for the aggressive growth, and these tumors frequently relapse.
To investigate the factors that may lead to aggressive meningioma, Raleigh’s team collected 280 human meningioma samples from 1990 to 2015. Using a range of techniques, including RNA sequencing and targeted gene expression profiling, the researchers searched for links between gene activity and protein production in these tumor and patients’ clinical outcomes. Finally, a gene called FOXM1 was found to be the core of the growth of invasive meningioma, and also an indicator of the subsequent adverse clinical outcomes, including death.
Vatsvaguriri vakawana zvakare hukama hutsva pakati pekuwandisa kwemamonyomaomas ane hukasha pamwe nekumisikidza nzira dzemascellular dzinoratidzira nzira, inonzi Wnt, iyo inowanzoita basa mukukura kweembryonic nekuumbwa kwetishu. Tichifunga kuti protein inogadzirwa neFOXM1 inogona kuendesa masaini munzira yeWnt, iyo data nyowani inoratidza kuti basa rekushandira pamwe reFOXM1 neWnt nzira inogona kutungamira mukuwedzera kwekuwedzera kwemamenomomaoma. Hypermethylation inogona kuve yekutanga kukonzeresa kwekuumbwa kweanesimba meningiomas.
Raleigh akati iro ramangwana basa rinoda kutsvaga kuti ndeapi majini FOXM1 anoshanda kufambisa meningioma kukura, uye vharira izvi zvinangwa nemakiriniki ekurapa. Zvinotarisirwa kuti pachave nemishonga yekumisa iyo pathogenesis yematumbo europi munzira iyi nekukurumidza uye kubatsira vazhinji vevarwere vegomarara.
